GlobalData
GlobalData

Press Release

Thailand looks to bolster leadership position in medical tourism with focus on medical robotics, says GlobalData

With an outstanding medical foundation that includes various internationally accredited medical facilities, qualified healthcare specialists and premium medical services along with a focus on medical robotics, Thailand is well-positioned to be the medical hub of Asia, according to GlobalData, a leading data and analytics company. Medical tourism is one of the main sectors driving the […]
Read more

ECCO 2019: Entyvio set to be most dominant drug in the UC landscape following VARSITY trial, says GlobalData

The results of the VARSITY trial, a head-to-head Phase IIIb double-blind, double-dummy, multicentre, active controlled study, that evaluates the efficacy and safety of Entyvio, compared to Humira in patients with moderate to severe ulcerative colitis (UC), were announced at the ECCO Conference 2019 in Copenhagen. Following this, Patrick Aiyes, Pharma Analyst at GlobalData, a leading […]
Read more

As National Colorectal Cancer Awareness Month draws attention to the disease, colorectal cancer screening tests market expected to surpass $2bn by 2028, says GlobalData

March is National Colorectal Cancer (CRC) Awareness Month, a time aimed at raising disease awareness and preventing future incident cases, primarily by encouraging individuals to participate in CRC screening programs. Alison Casey, Medical Devices analysts at GlobalData, commented, “Aging populations and increasing disease awareness mean that CRC screening has become a priority for many countries. […]
Read more

Deutsche and Commerzbank merger talks prompted by fears of foreign takeover, says GlobalData

Following the news of merger talks between Germany’s two largest banks, Deutsche and Commerzbank, Sean Harrison, Banking Analyst at GlobalData, a leading data and analytics company offers his comment: “These merger talks are unsurprising. Both banks have had a torrid time, suffering from poor profitability and inefficient operations. According to GlobalData’s Global Retail Banking Analytics tool […]
Read more

Translating new upstream development opportunities into tangible production increases will be key for China, says GlobalData

A steadily expanding economy and growing urbanization has led to rapid domestic energy consumption and made China increasingly dependent on foreign oil and gas. To improve domestic energy security, the country unveiled further reforms in 2018, which have prompted interest from international investors. However, translating this into tangible production increases will be the next challenge, […]
Read more

Oversubscribed Heathrow bond sale shows strong support despite looming spectre of Brexit, says GlobalData

Following yesterday’s (March 6) successful bond sale by Heathrow Airport Holdings Ltd, Nick Wyatt, Head of R&A, Travel & Tourism at GlobalData, offers his view: “There has been much doom-mongering with regards to Brexit, but the roaring success of Heathrow’s bond sale shows that investors are far from perturbed despite potential disruption in the eventuality […]
Read more

Norway leads new-build capex outlook in North Sea, says GlobalData

Norway is expected to spend the highest new-build capital expenditure (capex) of US$21.2bn on the development of the planned and announced projects, among the countries in the North Sea, during the period 2019–2025, according to GlobalData, a leading data and analytics company. The company’s report: ‘H1 2019 Production and Capital Expenditure Outlook for Key Planned […]
Read more

Humira approval for hidradenitis suppurativa treatment in Japan will bolster AbbVie’s profits, says GlobalData

AbbVie and Eisai announced recently that Humira, a fully human anti-TNF-α monoclonal antibody, has received additional approval for the treatment of hidradenitis suppurativa (HS) in Japan. This will strengthen AbbVie’s profits even though there is increasing competition from Humira biosimilars, according to GlobalData, a leading data and analytics company. The approval of this additional indication […]
Read more

Spinraza’s approval in China will help Biogen weather threats from strong pipeline of drugs, says GlobalData

Following the recent news that Biogen’s Spinraza (nusinersen) won approval from China’s National Medical Products Association (NMPA) as a treatment for spinal muscular atrophy (SMA), Vinie Varkey, MSc, Senior Neurology & Ophthalmology Analyst at GlobalData, offers her view: “The decision was not surprising given the recent efforts of NMPA to reform the process of approving […]
Read more

Payment segment emerges as lucrative investment avenue in Q4 2018, finds GlobalData

With consumers globally embracing financial technologies, digital payments firms are fast disrupting the hegemony of traditional players in the payment value chain. Against this backdrop, the payment segment is emerging as a lucrative investment avenue for merger and acquisition (M&A) activities and venture financers, according to GlobalData, a leading data and analytics company. The company’s […]
Read more

Esketamine set to change management treatment in patients with major depression disorder, says GlobalData

Following the news (5th March 2019) that the US FDA approved Johnson & Johnson’s nasal spray antidepressant, Esketamine, Alessio Brunello, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view:   “Esketamine, developed by J&J, is the first major depression disorder (MDD) treatment, with a novel mechanism of action, to be approved […]
Read more

Policy risks for Lebanon’s second offshore round despite stable fiscal terms

Political and economic instability may affect Lebanon’s second offshore licensing round, according to GlobalData, a leading data and analytics company. The company’s ‘Lebanon Upstream Fiscal and Regulatory Report’ states that Lebanon is expected to offer a stable fiscal framework for the second round, which comes amid continued interest in the Eastern Mediterranean from new discoveries […]
Read more
1 31 32 33 34 35 61